The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Open accessAbstract
BACKGROUND: A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown. METHODS: Applying the mendelian randomisation principle, we used single nucleotide polymorphisms (SNPs) in the gene IL6R to evaluate the likely efficacy and safety of IL6R inhibition for primary prevention of coronary heart disease. We compared genetic findings with the effects of tocilizumab reported in randomised trials in patients with rheumatoid arthritis. FINDINGS: In 40 studies including up to 133,449 individuals, an IL6R SNP (rs7529229) marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala) was associated with increased circulating log interleukin-6 concentration (increase per allele 9·45%, 95% CI 8·34-10·57) as well as reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38) and fibrinogen concentrations (decrease per allele 0·85%, 95% CI 0·60-1·10). This pattern of effects was consistent with IL6R blockade from infusions of tocilizumab (4-8 mg/kg every 4 weeks) in patients with rheumatoid arthritis studied in randomised trials. In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events (per allele odds ratio 0·95, 95% CI 0·93-0·97, p=1·53×10(-5)). INTERPRETATION: On the basis of genetic evidence in human beings, IL6R signalling seems to have a causal role in development of coronary heart disease. IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials. Genetic studies in populations could be used more widely to help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses. FUNDING: UK Medical Research Council; British Heart Foundation; Rosetrees Trust; US National Heart, Lung, and Blood Institute; Du Pont Pharma; Chest, Heart and Stroke Scotland; Wellcome Trust; Coronary Thrombosis Trust; Northwick Park Institute for Medical Research; UCLH/UCL Comprehensive Medical Research Centre; US National Institute on Aging; Academy of Finland; Netherlands Organisation for Health Research and Development; SANCO; Dutch Ministry of Public Health, Welfare and Sports; World Cancer Research Fund; Agentschap NL; European Commission; Swedish Heart-Lung Foundation; Swedish Research Council; Strategic Cardiovascular Programme of the Karolinska Institutet; Stockholm County Council; US National Institute of Neurological Disorders and Stroke; MedStar Health Research Institute; GlaxoSmithKline; Dutch Kidney Foundation; US National Institutes of Health; Netherlands Interuniversity Cardiology Institute of the Netherlands; Diabetes UK; European Union Seventh Framework Programme; National Institute for Healthy Ageing; Cancer Research UK; MacArthur Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“genetic evidence suggests that IL-6 may be causal for atherosclerotic cardiovascular disease, 24,25”
From Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genome-wide association studies (GWAS), meta-analysis, exome analysis and single nucleotide polymorphism (SNP) mapping have associated IL-6, IL-6R and gp130 with inflammatory diseases such as RA and coronary artery disease (263–269).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [265]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We also identified associations between IL6R pQTLs and CAD, rheumatoid arthritis and 7 other disease traits (Supplementary Table S12), thereby supporting the findings of the study69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“One large study reported a near significant effect ( P = 0.06) of a functional variant causing impaired signalling at the IL-6 receptor with reduced risk of developing diabetes mellitus 44.”
From Type 2 diabetes mellitus and psychological stress — a modifiable risk factor (2017) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“A previous study has shown a link between IL6R and CAD69.”
From Genetic determinants of plasma protein levels in the Estonian population (2024) · cites this paper as [69]
In the citing paper
“Confirming the role of IL-6 in health, in a large Mendelian randomization analysis, the IL6R SNP rs7529229, marking a non-synonymous IL6R variant (rs8192284; p.Asp358Ala), was associated with increased circulating IL-6 levels24.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“Variants in the IL6R gene have been found to be associated with increased risk of coronary artery disease24, rheumatoid arthritis, atrial fibrillation, and abdominal aortic aneurysm, and with increased susceptibility to asthma, type 1 diabetes, and depression36,37.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [24]
In the citing paper
“CETP inhibitors exert their relatively modest cardioprotective effects on the basis that in addition to their HDL-C raising effects, more potent CETP inhibitors also lower apolipoprotein B 22,23,75 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“The approach outlined here to obtaining a scaling estimate has generally held true for lipid-lowering therapies and risk of cardiovascular disease 22,23,40,92 but there are several potential reasons why the derivation of such a scaling for other therapeutic target-indication pairs may pose a challenge.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“However, using SNPs located in CETP associated with HDL-C at genome-wide significant levels in a drug-target MR suggests that modifying HDL-C via CETP, is likely to reduce risk of CHD 23,103 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“CETP 23 variants associate with of CHD; APOA1 117 variants do not associate with risk of CHD”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [23]
In the citing paper
“Various statistical methods have been proposed to reduce weak instrument bias due to sample overlap and bias due to winner’s curse (see Section 3) 43– 45 .”
From Guidelines for performing Mendelian randomization investigations (2020) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,762
Haploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,563
The Human Genome Browser at UCSC
Kent, W. J., Sugnet, C. W., Furey, T. S., Roskin, K. M., Pringle, T. H., Zahler, A. M., & Haussler, A. D. (2002) · Genome Research · doi:10.1101/gr.229102 · Cited by 10,400
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Cited by
Sorted by citations
Items 101–200 of 999
An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study
Yuan, S., & Larsson, S. C. (2020) · Diabetologia · doi:10.1007/s00125-020-05253-x · Cited by 242
Education and coronary heart disease: mendelian randomisation study
Tillmann, T., Vaucher, J., Okbay, A., Pikhart, H., Peasey, A., Kubinova, R., Pajak, A., Tamosiunas, A., Malyutina, S., Hartwig, F. P., et al. (2017) · BMJ · doi:10.1136/bmj.j3542 · Cited by 225
Inflammation and Stroke Risk: A New Target for Prevention
Kelly, P. J., Lemmens, R., & Tsivgoulis, G. K. (2021) · Stroke · doi:10.1161/strokeaha.121.034388 · Cited by 218
Ferrie, J. E., Kivimaki, M., Akbaraly, T. N., Singh-Manoux, A., Miller, M. A., Gimeno, D., Kumari, M., Davey Smith, G., & Shipley, M. J. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kwt072 · Cited by 218
Usual Blood Pressure and Risk of New-Onset Diabetes
Emdin, C. A., Anderson, S. G., Woodward, M., & Rahimi, K. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.059 · Cited by 216
Early vascular ageing in translation
Nilsson, P. M., Boutouyrie, P., Cunha, P., Kotsis, V., Narkiewicz, K., Parati, G., Rietzschel, E. R., Scuteri, A., & Laurent, S. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328361e4bd · Cited by 212
Hemingway, H., Asselbergs, F. W., Danesh, J., Dobson, R., Maniadakis, N., Maggioni, A. P., van Thiel, G. J. M. W., Cronin, M., Brobert, G., Vardas, P. E., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx487 · Cited by 218
Nyberg, S. T., Fransson, E. I., Heikkilä, K., Alfredsson, L. S., Casini, A., Clays, E., Bacquer, D. D., Dragano, N., Erbel, R., Ferrie, J. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067323 · Cited by 205
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
McLure, K. G., Gesner, E. M., Tsujikawa, L. M., Kharenko, O. A., Attwell, S., Campeau, E., Wasiak, S., Stein, A. J., White, A., Fontano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083190 · Cited by 200
The Two-Faced Cytokine IL-6 in Host Defense and Diseases
Narazaki, M., & Kishimoto, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113528 · Cited by 214
Hasturk, H., Abdallah, R., Kantarci, A., Nguyen, D., Giordano, N., Hamilton, J., & Van Dyke, T. E. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305324 · Cited by 199
Prins, B. P., Abbasi, A., Wong, A., Vaez, A., Nolte, I., Franceschini, N., Stuart, P. E., Guterriez Achury, J., Mistry, V., Bradfield, J. P., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001976 · Cited by 199
Causal Inference in Cancer Epidemiology: What Is the Role of Mendelian Randomization?
Yarmolinsky, J., Wade, K. H., Richmond, R. C., Langdon, R., Bull, C. J., Tilling, K. M., Relton, C. L., Lewis, S. J., Smith, G. D., & Martin, R. M. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-1177 · Cited by 189
Zanoli, L., Briet, M. B., Empana, J. P., Cunha, P., Maki-Petaja, K. M., Protogerou, A. D., Tedgui, A., Touyz, R. M., Schiffrin, E. L., Spronck, B., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002508 · Cited by 203
Avan, A., Tavakoly Sany, S. B., Ghayour‐Mobarhan, M., Rahimi, H. R., Tajfard, M., & Ferns, G. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26791 · Cited by 182
Stroke genetics: discovery, biology, and clinical applications
Dichgans, M., Pulit, S. L., & Rosand, J. M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30043-2 · Cited by 187
Perry, B. I., Upthegrove, R., Kappelmann, N., Jones, P. B., Burgess, S., & Khandaker, G. M. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.07.009 · Cited by 187
Holmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Wang, Q., Holmes, M. V., Smith, G. D., & Ala‐Korpela, M. (2017) · Diabetes Care · doi:10.2337/dc17-1642 · Cited by 182
Inflammatory Biomarkers and Atherosclerosis
Soeki, T., & Sata, M. (2016) · International Heart Journal · doi:10.1536/ihj.15-346 · Cited by 183
Buyken, A. E., Goletzke, J., Joslowski, G., Felbick, A., Cheng, G., Herder, C., & Brand-Miller, J. C. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.074252 · Cited by 180
The Role of Dietary Inflammatory Index in Cardiovascular Disease, Metabolic Syndrome and Mortality
Ruiz‐Canela, M., Bes‐Rastrollo, M., & Martínez‐González, M. Á. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081265 · Cited by 184
Interleukin-6 receptor pathways in abdominal aortic aneurysm
Harrison, S. C., Smith, A. J. P., Jones, G. T., Swerdlow, D. I., Rampuri, R., Bown, M. J., Folkersen, L., Baas, A. F., de Borst, G. J., Blankensteijn, J. D., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs354 · Cited by 174
Self-citationTamura, Y., Phan, C., Tu, L., Hiress, M. L., Thuillet, R., Jutant, E., Fadel, É., Savale, L., Huertas, A., Humbert, M. J. C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96462 · Cited by 182
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 186
Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease
Aday, A. W., & Ridker, P. M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00016 · Cited by 178
Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis
Bouras, E., Karhunen, V., Gill, D., Huang, J. V., Haycock, P., Gunter, M. J., Johansson, M., Brennan, P., Key, T. J., Lewis, S. J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02193-0 · Cited by 178
Neutrophil counts and cardiovascular disease
Luo, J. M., Thomassen, J. Q., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad649 · Cited by 183
Factors Associated With Plasma IL-6 Levels During HIV Infection
Borges, Á. H., O’Connor, J. L., Phillips, A. N., Rönsholt, F. F., Pett, S. L., Vjecha, M. J., French, M. A., & Lundgren, J. D. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv123 · Cited by 175
Rosa, M., Chignon, A., Li, Z., Boulanger, M., Arsenault, B. J., Bossé, Y., Thériault, S., & Mathieu, P. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0097-4 · Cited by 169
Inflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 176
The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications
Herder, C., Dalmas, É., Böni‐Schnetzler, M., & Donath, M. Y. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.08.001 · Cited by 176
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease
Weber, B., Giles, J. T., & Liao, K. P. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00969-7 · Cited by 185
Taylor, A. E., Davies, N. M., Ware, J. J., VanderWeele, T., Smith, G. D., & Munafò, M. R. (2014) · Economics & Human Biology · doi:10.1016/j.ehb.2013.12.002 · Cited by 166
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases
Shah, A. D., Denaxas, S., Nicholas, O., Hingorani, A. D., & Hemingway, H. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.022 · Cited by 168
Interleukin-6 Signaling Effects on Ischemic Stroke and Other Cardiovascular Outcomes
Georgakis, M. K., Malik, R., Gill, D., Franceschini, N., Sudlow, C. L. M., Dichgans, M., Lindström, S., Wang, L., Smith, E. N., Gordon, W., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.119.002872 · Cited by 182
Su, W., Gu, X., Dou, M., Duan, Q., Jiang, Z., Yin, K., Cai, W.-C., Cao, B., Wang, Y., & Chen, Y. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-331142 · Cited by 169
IL ‐6 in diabetes and cardiovascular complications
Qu, D. C., Liu, J., Lau, C. W., & Huang, Y. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12713 · Cited by 166
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., Bradwin, G., Hasan, A., & Rifai, N. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa160 · Cited by 169
Ferdinandy, P., Andreadou, I., Baxter, G. F., Bøtker, H. E., Davidson, S. M., Dobrev, D., Gersh, B. J., Heusch, G., Lecour, S., Ruiz‐Meana, M., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000348 · Cited by 170
Targeting the Immune System in Atherosclerosis
Zhao, T. X., & Mallat, Z. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.083 · Cited by 161
Statistical methods for cis‐Mendelian randomization with two‐sample summary‐level data
Gkatzionis, A., Burgess, S., & Newcombe, P. J. (2022) · Genetic Epidemiology · doi:10.1002/gepi.22506 · Cited by 159
Burgess, S., Mason, A. M., Grant, A. J., Slob, E. A. W., Gkatzionis, A., Zuber, V., Patel, A. R., Tian, H., Liu, C., Haynes, W. G., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.12.017 · Cited by 157
Ridker, P. M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab231 · Cited by 156
Garbers, C., Monhasery, N., Aparicio-Siegmund, S., Lokau, J., Baran, P., Nowell, M. A., Jones, S. A., Rose-John, S., & Scheller, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.05.018 · Cited by 155
Bacchiega, B. C., Bacchiega, A. B. S., Usnayo, M. J. G., Bedirian, R., Singh, G., & Pinheiro, G. D. R. C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005038 · Cited by 157
Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions
Ferguson, L. D., Siebert, S., McInnes, I. B., & Sattar, N. A. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0256-0 · Cited by 160
Periodontal therapy and cardiovascular risk
Orlandi, M., Graziani, F., & D'Aiuto, F. (2020) · Periodontology 2000 · doi:10.1111/prd.12299 · Cited by 155
Diogo, D., Bastarache, L. A., Liao, K. P., Graham, R., Fulton, R. S., Greenberg, J. D., Eyre, S., Bowes, J., Cui, J., Lee, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122271 · Cited by 154
Biological and functional multimorbidity—from mechanisms to management
Langenberg, C., Hingorani, A. D., & Whitty, C. W. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02420-6 · Cited by 153
Gene of the month: Interleukin 6 (IL-6)
Ataie-Kachoie, P., Pourgholami, M. H., Richardson, D. R., & Morris, D. L. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202493 · Cited by 153
Haapakoski, R., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.012 · Cited by 157
Libby, P. (2021) · Cells · doi:10.3390/cells10040951 · Cited by 158
Autoimmune diseases and atherosclerotic cardiovascular disease
Porsch, F., & Binder, C. J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01045-7 · Cited by 155
An atlas of genetic scores to predict multi-omic traits
Xu, Y., Ritchie, S. C., Liang, Y., Timmers, P. R. H. J., Pietzner, M., Lannelongue, L., Lambert, S. A., Tahir, U. A., May-Wilson, S., Foguet, C., et al. (2023) · Nature · doi:10.1038/s41586-023-05844-9 · Cited by 150
Integrative functional genomics identifies regulatory mechanisms at coronary artery disease loci
Miller, C. L., Pjanic, M., Wang, T., Nguyen, T., Cohain, A. T., Lee, J. D., Matic, L. P., Hedin, U., Kundu, R. K., Majmudar, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12092 · Cited by 141
Novel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
Novel biomarkers of cardiovascular disease: Applications in clinical practice
Lyngbakken, M. N., Myhre, P. L., Røsjø, H. R., & Omland, T. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1525335 · Cited by 155
Hamilton, F., Thomas, M., Arnold, D., Palmer, T., Moran, E., Mentzer, A. J., Maskell, N. A., Baillie, J. K., Summers, C., Hingorani, A. D., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004174 · Cited by 144
Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
Zhang, B., Shu, X., Delahanty, R., Zeng, C., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Wen, W., Long, J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv219 · Cited by 143
Khandaker, G. M., Zuber, V., Rees, J. M. B., Carvalho, L. A., Mason, A. M., Foley, C. N., Gkatzionis, A., Jones, P. B., & Burgess, S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0857-7 · Cited by 139
Catapano, A. L., Pirillo, A., & Norata, G. D. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13805 · Cited by 138
Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation
Riethmueller, S., Somasundaram, P., Ehlers, J. C., Hung, C.-W., Flynn, C. M., Lokau, J., Agthe, M., Düsterhöft, S., Zhu, Y., Grötzinger, J., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2000080 · Cited by 135
Monocyte Recruitment, Specification, and Function in Atherosclerosis
Kim, K.-W., Ivanov, S., & Williams, J. W. (2020) · Cells · doi:10.3390/cells10010015 · Cited by 139
Interleukin-6 and interleukin-11: same same but different
Garbers, C., & Scheller, J. (2013) · Biological Chemistry · doi:10.1515/hsz-2013-0166 · Cited by 134
Mendelian randomization for studying the effects of perturbing drug targets
Gill, D., Georgakis, M. K., Walker, V. M., Schmidt, A. F., Gkatzionis, A., Freitag, D. F., Finan, C., Hingorani, A. D., Howson, J. M. M., Burgess, S., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16544.2 · Cited by 286
Self-citationPrattichizzo, F., De Nigris, V., La Sala, L., Procopio, A. D., Olivieri, F., & Ceriello, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1810327 · Cited by 129
Overview of anti-inflammatory diets and their promising effects on non-communicable diseases
Yu, X., Pu, H., & Voss, M. (2024) · British Journal of Nutrition · doi:10.1017/s0007114524001405 · Cited by 134
† (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00034-0 · Cited by 132
Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis.
White, J., Sofat, R., Hemani, G., Shah, T., Engmann, J., Dale, C., Shah, S., Kruger, F. A., Giambartolomei, C., Swerdlow, D. I., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00386-1 · Cited by 132
Self-citationChen, L., Peters, J. E., Prins, B. P., Persyn, E., Traylor, M., Surendran, P., Karthikeyan, S., Yonova‐Doing, E., Angelantonio, E. D., Roberts, D. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33675-1 · Cited by 134
Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis
Li, B., Li, W., Li, X., & Zhou, H. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230142931 · Cited by 130
Borges, Á. H., O’Connor, J. L., Phillips, A. N., Neaton, J. D., Grund, B., Neuhaus, J., Vjecha, M. J., Calmy, A., Koelsch, K. K., & Lundgren, J. D. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw173 · Cited by 134
FPR2/ALXR Agonists and the Resolution of Inflammation
Corminboeuf, O., & Leroy, X. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501051x · Cited by 135
Meta-analysis investigating the role of interleukin-6 mediated inflammation in type 2 diabetes
Bowker, N., Shah, R. L., Sharp, S. J., Luan, J., Stewart, I. D., Wheeler, E., Ferreira, M. A. R., Baras, A., Wareham, N. J., Langenberg, C., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103062 · Cited by 134
Depression and Interleukin-6 Signaling: A Mendelian Randomization Study
Kelly, K. M., Smith, J. A., & Mezuk, B. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.02.019 · Cited by 117
Ataie-Kachoie, P., Pourgholami, M., & Morris, D. (2013) · Cytokine & growth factor reviews · doi:10.1016/j.cytogfr.2012.09.001 · Cited by 123
Reiner, A. P., Beleza, S. S., Franceschini, N., Auer, P. L., Robinson, J. G., Kooperberg, C. L., Peters, U., & Tang, H. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.07.023 · Cited by 128
Dhall, A., Patiyal, S., Sharma, N., Usmani, S. S., & Raghava, G. P. S. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa259 · Cited by 124
Abdominal aortic aneurysm—an independent disease to atherosclerosis?
Toghill, B. J., Saratzis, A. N., & Bown, M. J. (2017) · Cardiovascular Pathology · doi:10.1016/j.carpath.2017.01.008 · Cited by 120
Khandaker, G. M., Zammit, S., Burgess, S., Lewis, G., & Jones, P. B. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.11.020 · Cited by 118
Mendelian Randomization as a Tool for Cardiovascular Research
Levin, M. G., & Burgess, S. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.4115 · Cited by 123
High-risk periodontal pathogens contribute to the pathogenesis of atherosclerosis
Bale, B. F., Doneen, A. L., & Vigerust, D. J. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2016-134279 · Cited by 117
IL-6 and Cardiovascular Risk: A Narrative Review
Mehta, N. N., deGoma, E. M., & Shapiro, M. D. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01259-7 · Cited by 140
Therapeutics targeting persistent inflammation in chronic kidney disease
Machowska, A., Carrero, J. J., Lindholm, B., & Stenvinkel, P. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.012 · Cited by 117
Moreira, D. M., da Silva, R. L., Vieira, J. L., Fattah, T., Lueneberg, M. E., & Gottschall, C. A. M. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0094-z · Cited by 117
Circulating interleukin‐6 concentration and cognitive decline in old age: the PROSPER study
Mooijaart, S. P., Sattar, N. A., Trompet, S., Lucke, J., Stott, D. J., Ford, I., Jukema, J. W., Westendorp, R. G. J., & de Craen, A. J. M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12052 · Cited by 116
An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
Rao, V. U., Pavlov, A., Klearman, M., Musselman, D. R., Giles, J. T., Bathon, J. M., Sattar, N. A., & Lee, J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38920 · Cited by 118
Rod, N. H., Meena Kumari, B., Lange, T., Mika Kivimaki, B., Shipley, M. J., & Ferrie, J. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091965 · Cited by 116
Gelfand, J. M., Shin, D. B., Alavi, A. A., Torigian, D. A., Werner, T. J., Papadopoulos, M., Takeshita, J., Noe, M. H., Dey, A. K., Playford, M. P., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.07.679 · Cited by 113
Silvis, M. J. M., Demkes, E. J., Fiolet, A. T. L., Dekker, M., Bosch, L., van Hout, G. P. J., Timmers, L., & de Kleijn, D. P. V. (2020) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-020-10049-w · Cited by 115
Cai, T., Zhang, Y., Ho, Y.-L. A., Link, N., Sun, J., Huang, J., Cai, T. A., Damrauer, S. M., Ahuja, Y., Honerlaw, J. P., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2287 · Cited by 114
Bhattacharya, R., Zekavat, S. M., Uddin, M. M., Pirruccello, J. P., Niroula, A., Gibson, C. J., Griffin, G. K., Libby, P., Ebert, B. L., Bick, A. G., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1678 · Cited by 113
The metalloprotease ADAM17 in inflammation and cancer
Düsterhöft, S., Lokau, J., & Garbers, C. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.04.002 · Cited by 114
Management of inflammation in cardiovascular diseases
Goswami, S. K., Ranjan, P., Dutta, R. K., & Verma, S. K. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105912 · Cited by 111
Cardiovascular disease in patients with rheumatoid arthritis
Liao, K. P. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.07.006 · Cited by 108
Immunity, Inflammation, and Oxidative Stress in Heart Failure: Emerging Molecular Targets
Ayoub, K. F., Pothineni, N. V. K., Rutland, J. J., Ding, Z., & Mehta, J. L. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6752-z · Cited by 107
The role of hepcidin and iron homeostasis in atherosclerosis
Wunderer, F., Traeger, L., Sigurslid, H. H., Meybohm, P., Bloch, D. B., & Malhotra, R. K. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104664 · Cited by 109
Circulating Levels of Interleukin 1-Receptor Antagonist and Risk of Cardiovascular Disease
Herder, C., Gala, T. D. L. H., Carstensen‐Kirberg, M., Huth, C., Zierer, A., Wahl, S., Sudduth-Klinger, J., Kuulasmaa, K., Peretz, D., Ligthart, S., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309307 · Cited by 112
Metadata
- Authors
- Swerdlow, D. I.
- Affiliations
- University College London (GB)
- Corresponding author
- Daniel I. Swerdlow
- ORCID
- Daniel I. Swerdlow
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 379
- Issue
- 9822
- Pages
- 1214-1224
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3316968
- OpenAlex
- W2143727405
- Cited by
- 1,146
- References
- 100
- Citations by year
- 2026: 78 · 2025: 86 · 2024: 94 · 2023: 89 · 2022: 84 · 2021: 110 · 2020: 89 · 2019: 80 · 2018: 74 · 2017: 77 · 2016: 67 · 2015: 56 · 2014: 63 · 2013: 65 · 2012: 32
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion, cc-by)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Lithuanian University of Health Sciences (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- MRC population health scientist fellowship (G0802432)
- National Institutes of Health (NIH), the MRC, and the British Heart Foundation (BHF (RG/10/12/28456)
- BHF (Schillingford) clinical training fellowship (FS/07/011)
- US National Heart, Lung, and Blood Institute (HHSN268200900009C)
- National Human Genome Research Institute (U01HG005152)
- Cancer Research UK (C1298/A8362, C150/A5660)
- IKEM (Czech Republic) (00023001)
- National Institute for Healthy Ageing (05060810)
- NIH/NHLBI (5215810-55000000041)
- BHF (RG 08/008 and PG/07/133/24260, RG/04/003)
- Netherlands Organisation for Health Research and Development (90700342)
- BHF senior fellowship (FS 05/125)
- British Heart Foundation (RG/10/12/28456)
- contract no. (HHSN268200625226C)
- NHLBI in collaboration with MESA investigators (N01 HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and RR-024156)
- Wellcome Trust (064947/Z/01/Z and 081081/Z/06/Z)
- National Institute on Aging (1R01 AG23522-01)
- Intramural Research Program of the National Institute on Aging, NIH, Department of Health and Human Services (Z01 AG000954-06, ISGS (R01 NS42733), (R01 NS39987), Z01 AG000015-50)
- European Commission (QLG1-CT-2002-00896)
- Dutch Kidney Foundation (Grant E033)
- GENECURE (FP-6 LSHM CT 2006 037697)
- NIH (grant LM010098)
- The Netherlands Organisation for Health Research and Development (grant 916.761.70)
- European Union's Seventh Framework Programme (FP7/2007-2013)
- NHLBI (RFP-NHLBI-WH-11-10, HL36310)
- Veni grant Organization for Scientific Research (NWO) (2001.064)
- NIH; National Institute on Aging (AG13196)
- MRC (grant NHLBI 33014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- IL-6 receptor, tocilizumab, coronary artery disease, primary prevention, C-reactive protein, fibrinogen, rheumatoid arthritis, genetic variants, monoclonal antibodies
- MeSH terms
- Coronary Disease, Gene Frequency, Genotype, Humans, Phenotype, Genetic Variation, Signal Transduction, Randomized Controlled Trials as Topic, Treatment Outcome, Inflammation Mediators, Receptors, Interleukin-6, Polymorphism, Single Nucleotide, Genetic Association Studies, Mendelian Randomization Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
